In time for National Diabetes Month, Avapro is the First and Only Drug Approved by Health Canada for the Treatment of Early and Late Stage Renal (Kidney) Disease in Patients with High Blood Pressure and Type 2 Diabetes.
There is good news for Canadians with high blood pressure and type 2 diabetes. Bristol-Myers Squibb and Sanofi-Synthelabo today announced that Health Canada has approved Avapro® (irbesartan) for a new and unique indication: the treatment of early and late stage renal disease in patients with high blood pressure and type 2 diabetes mellitus. In Canada, approximately 8 million people suffer from high blood pressure(i) and approximately 2 million from diabetes.(ii) An estimated one-third of patients with diabetes will develop chronic kidney failure which requires dialysis or a kidney transplant.(i) The economic burden of diabetes and its complications is expected to reach $14 billion annually in health care costs and projections reveal an exponential increase in the number of deaths due to diabetes into the year 2016.(iii) Avapro, an angiotensin II receptor blocker (ARB), was originally approved by Health Canada in 1998 for the treatment of essential (mild, moderate and severe) hypertension.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!